The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice

Diabetologia

Volumn 53, Issue 3, 2010, Pages 552-561

  Hsieh, J ^a,b   Longuet, C ^c   Baker, C L ^b   Qin, B ^d   Federico, L M ^b   Drucker, D J ^c   Adeli, K ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d BELTSVILLE HUMAN NUTRITION RESEARCH CENTER   (United States)

Author keywords

Dipeptidyl peptidase 4; Incretins; Lipids; Triacylglycerol

Indexed keywords

EXENDIN (9-39); EXENDIN 4; FRUCTOSE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; HORMONE ANTAGONIST; INCRETIN; LIPOPROTEIN; SITAGLIPTIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; CHOLESTEROL; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; LIPID;

ANIMAL EXPERIMENT; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; IN VIVO STUDY; INTESTINE CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN SYNTHESIS; ANIMAL; C57BL MOUSE; CHEMISTRY; FEMALE; HAMSTER; MESOCRICETUS; METABOLISM; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; CHOLESTEROL; CRICETINAE; ENTEROCYTES; FEMALE; INCRETINS; LIPIDS; MALE; MESOCRICETUS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RECEPTORS, GLUCAGON; SIGNAL TRANSDUCTION; TRIGLYCERIDES;

EID: 77949273334     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-009-1611-5     Document Type: Article

References (33)

1. P Zimmet KG Alberti J Shaw 2001 Global and societal implications of the diabetes epidemic Nature 414 782 787 10.1038/414782a 1:CAS:528: DC%2BD38Xhtlymtg%3D%3D 11742409 (Pubitemid 34000780)
2. HN Ginsberg 2000 Insulin resistance and cardiovascular disease J Clin Invest 106 453 458 10.1172/JCI10762 1:CAS:528:DC%2BD3cXlvFCltLc%3D 10953019
3. N Mero M Syvanne MR Taskinen 1998 Postprandial lipid metabolism in diabetes Atherosclerosis 141 Suppl 1 S53 S55 10.1016/S0021-9150(98)00218-4 1:CAS:528:DyaK1MXnvFKltA%3D%3D 9888643
4. H Ohnishi S Saitoh S Takagi, et al. 2002 Relationship between insulin-resistance and remnant-like particle cholesterol Atherosclerosis 164 167 170 10.1016/S0021-9150(02)00057-6 1:CAS:528:DC%2BD38Xlt12lsbc%3D 12119206 (Pubitemid 34765649)
5. EJ Schaefer JR McNamara PK Shah, et al. 2002 Elevated remnant-like particle cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study Diabetes Care 25 989 994 10.2337/diacare.25.6.989 1:CAS:528:DC%2BD38XkslSksL0%3D 12032104 (Pubitemid 41110483)
6. WJ Lu Q Yang W Sun, et al. 2008 Using the lymph fistula rat model to study the potentiation of GIP secretion by the ingestion of fat and glucose Am J Physiol Gastrointest Liver Physiol 294 G1130 G1138 10.1152/ajpgi.00400.2007 1:CAS:528:DC%2BD1cXlvFCis78%3D 18372393
7. R Iakoubov A Izzo A Yeung CI Whiteside PL Brubaker 2007 Protein kinase Czeta is required for oleic acid-induced secretion of glucagon-like peptide-1 by intestinal endocrine L cells Endocrinology 148 1089 1098 10.1210/en.2006-1403 1:CAS:528:DC%2BD2sXitlWns7o%3D 17110421 (Pubitemid 46272798)
8. DJ Drucker 2006 The biology of incretin hormones Cell Metab 3 153 165 10.1016/j.cmet.2006.01.004 1:CAS:528:DC%2BD28Xislyhtr4%3D 16517403 (Pubitemid 43316521)
9. LL Baggio Q Huang TJ Brown DJ Drucker 2004 Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure Gastroenterology 127 546 558 10.1053/j.gastro.2004.04.063 1:CAS:528:DC%2BD2cXntlyjsLw%3D 15300587 (Pubitemid 39091903)
10. K Miyawaki Y Yamada N Ban, et al. 2002 Inhibition of gastric inhibitory polypeptide signaling prevents obesity Nat Med 8 738 742 10.1038/nm727 1:CAS:528:DC%2BD38XkvFehtrY%3D 12068290 (Pubitemid 34778728)
11. T Hansotia A Maida G Flock, et al. 2007 Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure J Clin Invest 117 143 152 10.1172/JCI25483 1:CAS:528:DC%2BD2sXmvV2qtA%3D%3D 17187081 (Pubitemid 46048461)
12. JJ Meier MA Nauck 2006 Incretins and the development of type 2 diabetes Curr Diab Rep 6 194 201 10.1007/s11892-006-0034-7 1:CAS:528:DC%2BD28XmtlKgsrk%3D 16898571
13. P Aschner MS Kipnes JK Lunceford, et al. 2006 Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes Diabetes Care 29 2632 2637 10.2337/dc06-0703 1:CAS:528:DC%2BD2sXhtVGhtA%3D%3D 17130196 (Pubitemid 44912190)
14. I Raz M Hanefeld L Xu, et al. 2006 Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus Diabetologia 49 2564 2571 10.1007/s00125-006-0416-z 1:CAS:528:DC%2BD28XhtFOqsrvF 17001471
15. RE Amori J Lau AG Pittas 2007 Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis JAMA 298 194 206 10.1001/jama.298.2.194 1:CAS:528:DC%2BD2sXnslSjuro%3D 17622601 (Pubitemid 47057766)
16. T Wasada K McCorkle V Harris, et al. 1981 Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs J Clin Invest 68 1106 1107 10.1172/JCI110335 1:CAS:528:DyaL3MXmtFGmt7o%3D 7287903
17. SJ Kim C Nian CH McIntosh 2007 Activation of lipoprotein lipase by glucose-dependent insulinotropic polypeptide in adipocytes. A role for a protein kinase B, LKB1, and AMP-activated protein kinase cascade J Biol Chem 282 8557 8567 10.1074/jbc.M609088200 1:CAS:528:DC%2BD2sXivV2nu7c%3D 17244606 (Pubitemid 47093503)
18. JJ Meier A Gethmann O Gotze, et al. 2006 Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans Diabetologia 49 452 458 10.1007/s00125-005-0126-y 1:CAS:528:DC%2BD28Xhs1WqtLc%3D 16447057 (Pubitemid 43277867)
19. X Qin H Shen M Liu, et al. 2005 GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats Am J Physiol Gastrointest Liver Physiol 288 G943 G949 10.1152/ajpgi.00303.2004 1:CAS:528:DC%2BD2MXktlSnsLg%3D 15677555 (Pubitemid 40563135)
20. C Taghibiglou F Rashid-Kolvear SC Van Iderstine, et al. 2002 Hepatic very low density lipoprotein-ApoB overproduction is associated with attenuated hepatic insulin signaling and overexpression of protein-tyrosine phosphatase 1B in a fructose-fed hamster model of insulin resistance J Biol Chem 277 793 803 10.1074/jbc.M106737200 1:CAS:528:DC%2BD38XjslGksQ%3D%3D 11598116 (Pubitemid 34952120)
21. M Haidari N Leung F Mahbub, et al. 2002 Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance. Evidence that chronic fructose feeding in the hamster is accompanied by enhanced intestinal de novo lipogenesis and ApoB48-containing lipoprotein overproduction J Biol Chem 277 31646 31655 10.1074/jbc.M200544200 1:CAS:528:DC%2BD38XmslOqt74%3D 12070142 (Pubitemid 34968968)
22. LM Federico M Naples D Taylor K Adeli 2006 Intestinal insulin resistance and aberrant production of apolipoprotein B48 lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia: evidence for activation of protein tyrosine phosphatase-1B, extracellular signal-related kinase, and sterol regulatory element-binding protein-1c in the fructose-fed hamster intestine Diabetes 55 1316 1326 10.2337/db04-1084 1:CAS:528:DC%2BD28XksFahtL4%3D 16644688 (Pubitemid 44195370)
23. C Taghibiglou A Carpentier SC Van Iderstine, et al. 2000 Mechanisms of hepatic very low density lipoprotein overproduction in insulin resistance. Evidence for enhanced lipoprotein assembly, reduced intracellular ApoB degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster model J Biol Chem 275 8416 8425 10.1074/jbc.275.12.8416 1:CAS:528:DC%2BD3cXit1entbg%3D 10722675 (Pubitemid 30180185)
24. C Taggart J Gibney D Owens, et al. 1997 The role of dietary cholesterol in the regulation of postprandial apolipoprotein B48 levels in diabetes Diabet Med 14 1051 1058 10.1002/(SICI)1096-9136(199712)14:12<1051::AID-DIA507>3. 0.CO;2-Q 1:STN:280:DyaK1c7hsFClug%3D%3D 9455933 (Pubitemid 28015390)
25. M Zoltowska E Ziv E Delvin, et al. 2003 Cellular aspects of intestinal lipoprotein assembly in Psammomys obesus: a model of insulin resistance and type 2 diabetes Diabetes 52 2539 2545 10.2337/diabetes.52.10.2539 1:CAS:528:DC%2BD3sXotVWhsLk%3D 14514638 (Pubitemid 37210543)
26. R Ebert M Nauck W Creutzfeldt 1991 Effect of exogenous or endogenous gastric inhibitory polypeptide (GIP) on plasma triglyceride responses in rats Horm Metab Res 23 517 521 10.1055/s-2007-1003745 1:CAS:528:DyaK38XltF2quw%3D%3D 1816061
27. LL Baggio Q Huang TJ Brown DJ Drucker 2004 A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis Diabetes 53 2492 2500 10.2337/diabetes.53.9.2492 1:CAS:528:DC%2BD2cXns1Shsbs%3D 15331566 (Pubitemid 39145610)
28. AJ Bergman C Stevens Y Zhou, et al. 2006 Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers Clin Ther 28 55 72 10.1016/j.clinthera.2006.01.015 1:CAS:528:DC%2BD28Xmtl2lsLo%3D 16490580 (Pubitemid 43254990)
29. MA Nauck G Meininger D Sheng L Terranella PP Stein 2007 Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial Diabetes Obes Metab 9 194 205 10.1111/j.1463-1326.2006.00704.x 1:CAS:528:DC%2BD2sXjs1SrtLw%3D 17300595 (Pubitemid 46206563)
30. N Matikainen S Manttari A Schweizer, et al. 2006 Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes Diabetologia 49 2049 2057 10.1007/s00125-006-0340- 2 1:CAS:528:DC%2BD28XnslSitbo%3D 16816950 (Pubitemid 44168471)
31. M Boschmann S Engeli K Dobberstein, et al. 2009 Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients J Clin Endocrinol Metab 94 846 852 10.1210/jc.2008-1400 1:CAS:528:DC%2BD1MXjt1Wmtr4%3D 19088168
32. E Levy D Sinnett L Thibault, et al. 1996 Insulin modulation of newly synthesized apolipoproteins B-100 and B-48 in human fetal intestine: gene expression and mRNA editing are not involved FEBS Lett 393 253 258 10.1016/0014-5793(96)00896-4 1:CAS:528:DyaK28Xls1KmtLc%3D 8814300 (Pubitemid 26298106)
33. C Longuet EM Sinclair A Maida, et al. 2008 The glucagon receptor is required for the adaptive metabolic response to fasting Cell Metab 8 359 371 10.1016/j.cmet.2008.09.008 1:CAS:528:DC%2BD1cXhtlOgur7P 19046568